InsiderTrades

Form 4 for TRVI Trevi Therapeutics, Inc.

Accepted 2025-03-25 00:00:00 ET · period of report 2025-03-21 · accession 0000950170-25-044436 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-25 2025-03-21 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $1.43 +5,263 218.6K +2% +$7,526
D 2025-03-25 2025-03-21 TRVI GOOD JENNIFER L Pres, CEO, Dir S - Sale+OE $6.58 -5,263 213.3K -2% -$34.6K
D 2025-03-25 2025-03-21 TRVI GOOD JENNIFER L Pres, CEO, Dir M - OptEx $0.00 -5,263 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-03-21 M A 5,263 $1.43 218,576 D — —
2 Common Common Stock 2025-03-21 S D 5,263 $6.58 213,313 D — — (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3 Derivative Stock Option (right to buy) 2025-03-21 M D 5,263 $0.00 0 D $1.43 · — to 2025-05-14 5,263 Common Stock (F2) This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019.